A national clinical trial, funded by NIH, tests benfotiamine, a synthetic vitamin B1, for treating mild cognitive impairment and early Alzheimer's disease. The trial, led by Burke Neurological Institute, UC San Diego, and Columbia University, aims to evaluate benfotiamine's cognitive effects and safety profile. Enrollment targets 406 participants aged 50-89 across 50 U.S. sites.